Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03114722
Other study ID # 2016/01420
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received March 20, 2017
Last updated June 14, 2017
Start date July 31, 2017
Est. completion date December 30, 2018

Study information

Verified date March 2017
Source National University Hospital, Singapore
Contact Soo Chin Lee
Phone (65) 6779 5555
Email soo_chin_lee@nuhs.edu.sg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective, randomized, non-blinded study. 1 group will be assigned the standard arm with use of heparinised saline (10U/ml) lock in between each catheter use. This is consistent with the standard procedure of PICC care in the investigators' centre. The second group will be assigned the intervention with use of 4% citrate lock (Dirinco Citra-Lock 4%) in between each catheter use.


Description:

PICC occlusion in patients requiring long-term central line access for chemotherapy is a recurrent issue. Occlusion is usually managed by administration of fibrinolytic agents, and subsequent removal and re-insertion if unsuccessful.

Locally, the current clinical practice is to use heparinised saline at a concentration of 10U/ml as a locking agent in between use of the PICC line to prevent occlusion. Citrate 4% has antithrombotic and antibacterial properties, which makes it potentially superior to heparin as a locking agent. Citrate chelates ionised calcium in blood, inhibiting calcium-dependent clotting pathways. Also, as a chelating agent, it results in inhibition of growth of micro-organisms. Citrate-based anticoagulation is often preferred over heparin because of its safety and rapid systemic clearance. Citrate also is safe for heparin induced thrombocytopenia patients.

The effects of each agent have been compared in renal patients with central lines on haemodialysis. These studies have demonstrated that 4% citrate is at least equivalent (MacRae, 2008) or even superior (Grudzinski, 2007) to heparin 5000U/ml in preventing catheter occlusions, and superior in preventing infection (Weijmer, 2002).

This study is a prospective, randomized, non-blinded study. 1 group will be assigned the standard arm with use of heparinised saline (10U/ml) lock in between each catheter use. This is consistent with the standard procedure of PICC care in the investigators' centre. The second group will be assigned the intervention with use of 4% citrate lock (Dirinco Citra-Lock 4%) in between each catheter use.

Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends. A standardised data tracking form will be used to assess baseline characteristics as well as number of times urokinase was used. Nursing documentation regarding each PICC flushing (standard documentation as per hospital protocol) will be evaluated for number of discrete attempts made to troubleshoot lines without use of urokinase. Positive blood culture results will be recorded for each patient.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 130
Est. completion date December 30, 2018
Est. primary completion date July 31, 2018
Accepts healthy volunteers No
Gender All
Age group 21 Years to 99 Years
Eligibility Inclusion Criteria:

- Age more than or equal to 21 years.

- Histologic or cytologic diagnosis of haematological or oncological malignancy

- Signed informed consent from patient or legal representative

- Patients on antiplatelet therapy may be recruited to the study

Exclusion Criteria:

- Pregnancy.

- Anticoagulation - warfarin or heparin or novel oral anticoagulants

- Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Citrate 4%
In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
Heparinised saline (10U/ml)
In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends

Locations

Country Name City State
Singapore Nationa University Hospital Singapore

Sponsors (1)

Lead Sponsor Collaborator
National University Hospital, Singapore

Country where clinical trial is conducted

Singapore, 

References & Publications (4)

Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium citrate 4% locking solution for central venous dialysis catheters--an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant. 2007 Feb;22(2):471-6. Epub 2006 Oct 25. — View Citation

Macrae JM, Dojcinovic I, Djurdjev O, Jung B, Shalansky S, Levin A, Kiaii M. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clin J Am Soc Nephrol. 2008 Mar;3(2):369-74. doi: 10.2215/CJN.01760407. — View Citation

Strauss RG. Mechanisms of adverse effects during hemapheresis. J Clin Apher. 1996;11(3):160-4. Review. — View Citation

Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant. 2002 Dec;17(12):2189-95. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of catheter occlusion Compare the rates of catheter occlusion in patients who receive citrate 4% as a locking agent, versus those who receive heparinised saline (10U/ml). From post insertion to 6 months or until the catheter is removed, whichever is earlier.
Secondary Line troubleshooting to compare the time to requiring troubleshooting of the line but not amounting to urokinase use From post insertion to 6 months or until the catheter is removed, whichever is earlier.
Secondary Catheter associated bacteraemia to compare the time to development of catheter associated bacteraemia From post insertion to 6 months or until the catheter is removed, whichever is earlier.
Secondary Bleeding complications to compare the time to development of bleeding complications, either local or systemic. From post insertion to 6 months or until the catheter is removed, whichever is earlier.
See also
  Status Clinical Trial Phase
Completed NCT05371418 - Comparative Clinical and Radiographical Evaluation of Treatment of Angular Bone Defect Related to Over Erupted Tooth Using GTR Followed by Orthodontic Intrusion Versus Orthodontic Intrusion Followed by GTR N/A
Not yet recruiting NCT05440084 - Impact of CTO PCI (Chronic Total Occlusion Percutaneous Intervention) on Regular Physical Activity
Completed NCT06343454 - The Effect of Different Head Positions on Occlusal Contacts During Digital Interocclusal Bite Registration N/A
Recruiting NCT05507164 - Characterization of the Temporo-masseteric Nerve Block (TMNB) in Healthy Subjects Phase 2
Completed NCT05051878 - Effect of T-scan Occlusal Analysis and Adjustment vs Articulating N/A
Recruiting NCT06365528 - Tunneled Peripherally Inserted Central Catheter (PICC) in Adult Patients and Associated Outcomes N/A
Completed NCT05948254 - Utilized Scan Body Technique For Triple Function N/A
Not yet recruiting NCT06052501 - 3D Evaluation of the Lip Support in a Full-arch Implant-supported Rehabilitations
Completed NCT03332264 - Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions N/A
Recruiting NCT05780619 - Diagnostic Performance of the Resistance Index (RI) for the Assessment of Cerebral Vasoreactivity in Transcranial Doppler
Completed NCT01131754 - Heparin 100U/L for Prevention of PVC Complications Phase 3
Terminated NCT03248739 - Comparison of EVD Catheter Diameter on Occlusion and Replacement N/A
Completed NCT04701970 - Effect of Mandibular Complete Dentures Relining on Occlusal Force Distribution N/A
Completed NCT05637372 - Relationships Between Anterior and Condylar Guidance - Comparison by CBCT and Electronic Axiography
Not yet recruiting NCT06402045 - Assessment of the Occlusal Characteristics and Orthodontic Treatment Needs for Egyptian Children( 6-12)years Old
Completed NCT01570114 - Covered Metallic Stent and Benign Colonic Strictures Phase 2
Completed NCT04798729 - Comparison of Two Different Digital Methods in Occlusal Analysis
Completed NCT05949151 - Occlusal Forces and Muscle Activity in Fixed Versus Removable Mandibular Implant Supported Overdenture N/A
Completed NCT05490797 - Effects of Mobile Application Dexteria Fine Motor Skills on Hand Dexterity and Grip Strength in Chronic Stroke Patients N/A
Not yet recruiting NCT04940702 - Effectiveness of Focal Vibration and Blood Flow Restriction Within a Multicomponent Exercise Programme. N/A